A Real-world Study of Adebrelimab Combined With Chemotherapy±Chest Radiotherapy in Patients With Extensive Stage Small Cell Lung Cancer

Launched by HEBEI MEDICAL UNIVERSITY FOURTH HOSPITAL · Mar 14, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the combination of a medication called Adebrelimab with chemotherapy and possibly chest radiation therapy for patients with extensive stage small cell lung cancer. The goal is to see how effective and safe this treatment is for patients in real-world settings, meaning outside of traditional clinical trials. The researchers are currently looking for participants who are 18 years or older and have been diagnosed with extensive stage small cell lung cancer confirmed by a medical test. It's important that participants have normal function of their major organs and are willing to follow the study guidelines.

If you or someone you know is considering joining this trial, participants can expect to receive the new treatment and undergo regular check-ups to monitor their health and progress. However, individuals with certain health conditions, serious allergies, or a history of drug abuse may not be eligible to participate. This study aims to provide valuable information about a promising new treatment approach for small cell lung cancer, which could help improve outcomes for patients facing this challenging diagnosis.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age:≥18 years old;
• • 2. Patients with extensive stage small cell lung cancer confirmed by histopathology;
• • 3. Normal function of major organs;
• • 4. Participants were willing to join in this study, and written informed consent, good adherence, cooperate with the follow-up.
• Exclusion Criteria:
• • 1. Patients with drug allergy sufferers;
• • 2. Serious and uncontrolled organic lesions or infections, such as decompensated heart, lung, kidney failure, etc;
• • 3. History of psychiatric drugs abuse and can't quit or patients with mental disorders;
• • 4. The researchers think inappropriate.